Arthur stillman m d ph d pi pamela woodard m d study co chair
This presentation is the property of its rightful owner.
Sponsored Links
1 / 12

Arthur Stillman, M.D., Ph.D., PI Pamela Woodard, M.D., Study Co-chair PowerPoint PPT Presentation


  • 59 Views
  • Uploaded on
  • Presentation posted in: General

R andomized  E valuation of Patients with S table Angina 
 C omparing U tilization of Diagnostic  E xaminations. Arthur Stillman, M.D., Ph.D., PI Pamela Woodard, M.D., Study Co-chair. COURAGE Trial. 2287 patients with stable angina (CCS I-III) At least one vessel with ≥ 70% stenosis

Download Presentation

Arthur Stillman, M.D., Ph.D., PI Pamela Woodard, M.D., Study Co-chair

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Arthur stillman m d ph d pi pamela woodard m d study co chair

Randomized Evaluation of Patients with Stable Angina 
Comparing Utilization of Diagnostic Examinations

Arthur Stillman, M.D., Ph.D., PI

Pamela Woodard, M.D., Study Co-chair


Courage trial

COURAGE Trial

  • 2287 patients with stable angina (CCS I-III)

  • At least one vessel with ≥ 70% stenosis

  • Objective evidence of ischemia

  • Randomized to OMT vs. OMT + PCI

  • Mean f/u 4.6 years

  • No difference in death or MI oranginal symptoms

Boden WE, et al. N Engl J Med. 2007 Apr. 12;356(15):1503–1516.


Primary aim

Primary Aim

  • To compare outcomes of participants with symptoms of stable angina or angina equivalent evaluated with an anatomic imaging strategy using CCTA as initial method of CAD diagnosis (Group A) to a combined functional and anatomic imaging strategy of SPECT MPI/ICA (Group B) as a guide to OMT.


Secondary aims

Secondary Aims

  • To evaluate the ability of available prognostic indices to predict revascularization or MACE using CCTA information and to develop new indices using the RESCUE trial data.

  •  To determine the cost, effectiveness, and incremental cost-effectiveness of CCTA versus SPECT MPI/ICA in the evaluation of participants with symptoms of stable angina.

  •  To compare angina symptoms and self-reported health status of participants with symptoms of stable angina undergoing CCTA as initial method of CAD diagnosis to SPECT MPI/ICA as a guide to OMT.


Eligibility

Eligibility

  • Patients ages 40 or older presenting with symptoms of stable angina CCS Class I to III or angina equivalent, with or without known CAD, with planned non-invasive imaging for diagnosis may enroll in the study


Inclusion criteria

Inclusion Criteria

  • Willing and able to provide a written informed consent;

  • 40 years or older;

  • Presentation with symptoms of stable angina (CCS Class I to III) or angina equivalent with or without known CAD;

  • Planned non-invasive imaging for CAD diagnosis;

  • Able to tolerate CCTA or SPECT MPI per randomization as required by protocol, to be performed at an ACRIN-qualified facility with a RESCUE-qualified scanner.


Exclusion criteria

Exclusion Criteria

  • Prior revascularization;

  • NOT SUITABLE TO UNDERGO CT WITH AN IODINATED CONTRAST AGENT:

    • Known allergy-like reaction to contrast media

    • Renal insufficiency or failure (GFR) < 30 mL/min/1.73 m2 

  • Atrial fibrillation or significant arrhythmia

  • AMI

  • Unstable angina and symptoms refractory to maximal oral and intravenous medical therapy (persistent CCS Class IV);

  • History of known left ventricular ejection fraction < 45%; Acute ischemia

  • Pregnant

  • Pacemaker


Exclusion criteria cont

Exclusion Criteria cont.

  • Pulmonary edema or heart failure unresponsive to std medical therapy;

  • Valvular heart disease likely to require surgery in 18 months;

  • Congenital heart disease or cardiomyopathy likely to affect prognosis during follow up;

  • Significant hypertension unresponsive to medical therapy;

  • Severe non-cardiovascular comorbidity - survival < 12 months);

  • Prior imaging evaluation for this episode of symptoms within 72 hours

  • BMI >40kg/m2


What is omt

What is OMT?

  • Antiplatelet such as aspirin or clopidogrel, if participant is aspirin intolerant

  • Statin with target LDL cholesterol of 70 mg/dL

  • Anti-hypertensive/anti-anginal beta blocker with BP goal of 130/80 Hg/mm and reduced CCS angina class

  • Additional anti-hypertensive (amlodipine or ACE-inhibitor) as needed

  • Additional anti-anginal, as needed


What is omt1

What is OMT?

  • ACE-inhibitor (lisinopril) or angiotensin II receptor antagonist (Losartan) if ACE-inhibitor not tolerated, for all participants with LV EF <=40%

  • Attempt to raise HDL cholesterol, > 40 mg/dL in men and > 50 mg/dL in women, with exercise, extended release niacin or fibrates alone or in combination once LDL is at goal

  • Medications for diabetes control, with target HbA1c< 7%

  • Smoking cessation

  • Exercise regimen appropriate to diagnosis

  • Nutritional/dietary modification


Www rescuetrial org

WWW. RESCUETRIAL.ORG


  • Login